Back to GetFilings.com
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934.
For the fiscal year ended September 30, 1996.
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934. [FEE REQUIRED]
For the transition period from ____________________ to
________________
Commission File Number:
001-10382
VALLEY FORGE SCIENTIFIC CORP.
(Exact name of registrant as specified in its charter)
PENNSYLVANIA 23-2131580
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
136 Green Tree Road, Oaks, Pennsylvania 19456
(Address of principal executive offices and zip code)
Telephone: (610) 666-7500
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Name of Each Exchange
Title of Each Class on which Registered
Common Stock, no par value Boston Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
Yes X No _____
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
or Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to
this Form 10-K. X
The aggregate market value of voting stock held by non-affiliates of the
registrant, computed by reference to the closing bid and ask prices as reported
by the NASDAQ system on December 17, 1996 as $11,787,055.
At December 17, 1996 there were 8,229,384 shares of the Registrant's
Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
As stated in Part III of this annual report on Form 10-K, portions of the
following documents are incorporated herein by reference:
Definitive Proxy Statement for the Annual
Meeting of Stockholders of the Registrant,
or an Amendment to this Annual Report on
Form 10-K, to be filed within 120 days
after the end of the fiscal year covered by
this Annual Report on Form 10-K.
PART I
Item 1. BUSINESS
Nature of Business
Valley Forge Scientific Corp. and its subsidiaries (collectively referred
to as the "Company") is principally engaged in the development and
manufacture of medical devices and other healthcare products. The Company
is a leading manufacturer of bipolar electrosurgical products. Through its new
generation of products, the Company has begun to broaden the market for its
products from neurosurgery and other microsurgery disciplines into other
surgery fields. The Company sells its products to or through national and
international distributors, which include affiliates of major healthcare
corporations. The Company was incorporated in the Commonwealth of
Pennsylvania on March 27, 1980.
The Company's principal products consist of bipolar electrosurgical
systems and related products and accessories. These bipolar electrosurgical
systems are based on patented circuitry and allow a surgeon to coagulate blood
vessels and/or cut tissue. Bipolar coagulation and cutting are conducted
through the use of a surgical hand-held instrument, which is connected via a
bipolar cord to the solid state microprocessor controlled generator.
In bipolar electrosurgery, the current flow occurs at the tips of a
bipolar instrument. This is quite different from conventional monopolar
electrosurgical systems, in which the current passes from an active pen
electrode through the patient to a grounding pad which acts as a dispersive
electrode. The Company's bipolar electrosurgical systems enable a surgeon to
bloodlessly cut, core and divide tissue without the use of a grounding pad and
its inherent safety hazards.
To provide irrigation for the bipolar electrosurgical systems, the
Company also manufactures and sells the MALIS Irrigation System. The
irrigation system provides controlled irrigation for bipolar cutting and
coagulation in a wet surgical field. The disposable MALIS bipolar
cord/irrigation tubing set ("C/T Set"), which is manufactured and sold by the
Company, is used to connect a surgical hand-held instrument to both the
irrigation module and the bipolar electrosurgical generator.
The Company has developed bipolar instruments which are to be used
with the Company's bipolar electrosurgical generators for hospital and office
procedures in the fields of neurosurgery, gynecology, urology, arthroscopy,
laparoscopy and plastic surgery. The bipolar instruments are connected to the
bipolar electrosurgical generator through a C/T Set or a bipolar cord.
The Company also manufactures and sells a disposable
cardiopulmonary resuscitation (CPR) mask system, surgical magnifying
loupes, a microsurgical stool and titanium surgical mesh.
Of the Company's $3,424,589 in sales in fiscal 1996, approximately
89% were made to Johnson & Johnson Professional, Inc. ("J & J"), formerly
known as Codman & Shurtleff, Inc., as compared to 76% and 90% in fiscal
1995 and 1994, respectively. The bipolar electrosurgical systems and the
irrigation system accounted for approximately 54% of the Company's sales
in fiscal 1996 and approximately 69% and 67% of the sales in fiscal 1995 and
1994, respectively. Sales of C/T Sets amounted to approximately 35% of the
Company's sales in fiscal 1996 and approximately 28% and 27% in 1995 and
1994, respectively.
Developments
In the second quarter of 1996, the Company received permission from
the United States Food and Drug Administration ("FDA") to market its new
VFS 300 bipolar electrosurgical generator which enables a physician to cut
tissue and/or coagulate blood vessels while the electrodes are totally
submerged in electrically conducted fluids, such as saline.
In the second quarter of 1996, the Company commenced selling its
VFS 200 bipolar electrosurgical system for use in magnetic imaging therapy,
which involves using magnetic resonance imaging equipment in conjunction
with an operative procedure, generally a tumor biopsy. To the Company's
knowledge, the VFS 200, with its unique circuitry, is the only electrosurgical
system which can be used in the same room with MRI equipment.
In March 1996, the Company modified its distribution agreement for
the CPR mask system with CDX Corporation from an exclusive distribution
agreement to a nonexclusive distribution agreement. The Company, through
a subsidiary, has commenced marketing the CPR mask system directly with
other customers and distributors.
In March 1996, the Company received FDA permission to market its
new line of bipolar cutting loops which are used in conjunction with the
Company's bipolar generators for use in all procedures which monopolar
generators are used.
In the third quarter of 1996, the Company's principal customer,
Johnson & Johnson Professional, Inc. commenced marketing of the "Malis
Synergy Bipolar System" which is used for coagulation in neurosurgery
procedures.
Products
The Company's business constitutes a single business segment.
Bipolar Electrosurgical Systems
MALIS* CMC-III High Power Bipolar Cutting/Coagulation System.
This third generation system was first introduced into the neurosurgery market
by J & J in October 1991. The MALIS* CMC-III High Power
Cutting/Coagulation System provides many times the power of the CMC-II
system in the cutting mode, and allows the surgeon to cut through any tissue.
The MALIS* CMC-III High Power Bipolar System was designed to replace
the MALIS* CMC-II bipolar system.
(* A registered trademark of Dr. Leonard I. Malis)
MALIS* CMC-III International Bipolar Cutting/Coagulation System.
This system incorporates the same features as the MALIS* CMC-III, with
certain modifications in order to meet the current standards for marketing the
unit worldwide. The unit has received IEC-601certification and now bears the
international "CE" mark.
MALIS* Bipolar Synergy System. A 50 watt coagulator for
neurosurgical use with updated coagulation technology. This unit is designed
to replace the MALIS* Precision Control Bipolar Coagulator.
Bipolar Endoscopic Coagulator. This generator is used as a coagulator
in endoscopic procedures, and is the subject of an existing distribution
agreement with Boston Scientific Corporation. The product is marketed by the
Microvasive division of Boston Scientific Corporation under its "Symmetry
Endo-Bipolar Generator" tradename.
MALIS* CMC-II Coagulator and Cutting System. A solid state,
microprocessor controlled bipolar electrosurgical system which allows a
surgeon to coagulate vessels and/or cut tissue at various power levels during
surgical procedures. The unit contains a voice feature, which informs the
surgeon of the power setting. The cutting feature of this system is primarily
used for coring during microsurgical procedures.
MALIS* International CMC-II Bipolar Coagulator and Cutting
System. Incorporates the same features as the MALIS CMC-II Coagulator
and Cutting System, with certain modifications in order to meet the standards
for sale in Europe. The unit has received IEC-601 certification.
Padgett Bipolar Cutter/Coagulator for Plastic/Reconstructive Surgery.
This generator has been developed for use by plastic surgeons to minimize
blood loss and post-operative scarring of tissue. The Company has received
FDA permission to market the generator. This generator is being marketed by
Padgett Instruments, Inc. pursuant to an existing distribution agreement.
Bi-Safe-I Cutter/Coagulator for Office Gynecological Procedures.
This generator meets the need for the bipolar modality in the physician's office
and offers significant cost and time savings over other available equipment.
The Company is marketing the generator through an independent
representative and intends to market the system through regional or national
distributors.
VFS 200 Bipolar System. This system is used in magnetic imaging
therapy, which uses magnetic resonance imaging equipment in conjunction
with operative procedures, generally a tumor biopsy. To the Company's
knowledge, the VFS 200, with it unique circuitry, is the only electrosurgical
system which can be used in the same room with MRI equipment.
MALIS* Irrigation System
The MALIS* Irrigation System is principally used in conjunction with
the Company's bipolar electrosurgical systems to provide controlled irrigation
for bipolar coagulation and cutting in a wet surgical field. The system consists
of an impulse pumped electrical generator which pumps and regulates the flow
of liquid through irrigation tubing, including, the disposable MALIS C/T Set,
which is manufactured and sold by the Company. The irrigation system may
also be used as a stand-alone unit.
Other Products
MALIS* Bipolar Cord/Irrigation Tubing Set. A disposable coextruded
bipolar forceps cord combined with an irrigation tubing set which
simultaneously delivers electrical current and irrigation fluid to a surgical
hand-held instrument. A new C/T Set is used for each surgical procedure. The
C/T Set is used in conjunction with the Company's bipolar electrosurgical
systems and the irrigation system.
CPR Mask System. This is a single-use disposable cardiopulmonary
resuscitation (CPR) mask system. In 1995, the system was redesigned to
incorporate design suggestions from principal customers. The product is
distributed by CDX, Inc. and is being marketed independently by the
Company. In 1996, the Company was granted a United States patent on the
mask system.
Titanium Surgical Mesh. Interwoven titanium used in neurosurgery
for the repair of skull and spinal column defects.
Surgical Magnifying Loupes. The loupes enable the surgeon to
magnify the surgical field. The product's multi-lens design provides correction
of spherical and color aberrations and maximum depth of field. The loupes
are presently available at powers of 2.5x, 3.25x and 4.0x magnification. The
loupes are sold under the MALIS* and NEUROPTIC trademarks.
Surgical Stool. A battery operated electrically controlled stool which
allows the surgeon to adjust his seating position up or down as the microscope
is raised or lowered throughout the surgical procedure. The product has been
designed for surgeons in all disciplines who use microscope magnification.
The surgical stool is sold under the MALIS* and SCOPEMATE trademarks.
New Products to be Introduced into the Market
The Company has developed several new bipolar generators, which
are based on the technology employed in the MALIS* High Power Bipolar
Cutting and Coagulation System, as well as bipolar instruments which are to
be used in conjunction with these new generators. These products are designed
to be sold in the neurosurgery, orthopedic, laparoscopic, urology, gynecology
and plastic surgery fields.
Bipolar Electrosurgical Pen. A final preproduction prototype of a
hand-held disposable bipolar electrosurgical pen has been completed, and the
Company has received permission to market this product from the FDA. The
pen is designed to be used with the MALIS* High Power Bipolar
Cutting/Coagulation System for neurosurgery and other surgical disciplines.
The Company completed clinical testing of the product and has been preparing
the product for production.
Bipolar Handswitched Electrosurgical Pen. The Company has
designed a hand-held disposable pen with hand switches for activating cutting
and/or coagulation. The pen is designed to be used with the MALIS* High
Power Bipolar Cutting/Coagulation System for orthopedic surgery.
Bi-Safe-II High Power Bipolar Cutter/Coagulator for OB/GYN
Procedures. The Company has developed a unique high power bipolar
cutter/coagulator for use in OB/GYN hospital procedures. This generator has
features which are unique and are designed to reduce the time required for
surgical procedures. The Company has received FDA permission to market
the generator and intends to market the system through regional or national
distributors.
MINI-SYMM Endo-Bipolar Coagulator. the generator is a small
version of the Symmetry System being marketed by the Microvasive Division
of Boston Scientific Corporation. Boston Scientific Corporation plans to sell
the MINI-SYMM System as a lower price alternative to the Symmetry System.
VFS 300 High Power Bipolar Cutter/Coagulator for Urological
Procedures. This unit has a technology which enables the physician to cut
tissue and/or coagulate blood vessels while the electrodes are totally
submerged in electrically conducted fluids, such as saline. The Company has
received FDA permission to market this system and intends to market the
system through regional or national distributors.
Bipolar Endoscopic and Laparoscopic Instruments. The Company has
developed preproduction prototypes of endoscopic and laparoscopic
instruments to be used in conjunction with the Company's High Power Bipolar
Cutting/Coagulation Systems. The Company has received permission to
market these products from the FDA. The Company intends to market these
instruments through regional or national distributors.
Bipolar Loop Electrodes. The Company has developed preproduction
prototypes of improved bipolar loop electrodes with modifications of the alloy
to provide faster and cleaner cutting. The loop electrodes are to be used in
conjunction with the Company's Bipolar Cutting/Coagulation Systems. The
Company has received FDA permission to market the loop electrodes.
Manufacturing and Supplies
For over 14 years, prior to August 31, 1994, the manufacturing,
assembly and packaging of the Company's electrosurgical products were
subcontracted to Diversified Electronic Corporation ("Diversified"), a
specialty electronics manufacturer, which provided contract manufacturing and
research and development to an established base of customers. On August 31,
1994, the Company vertically integrated the manufacturing, assembly and
packaging of its electrosurgical generators by acquiring Diversified. Since
August 31, 1994, Diversified Electronics Company, Inc. ("DEC"), a wholly
owned subsidiary of the Company, has conducted the operations of Diversified
in substantially the same manner as conducted by Diversified prior to the
acquisition.
The Company purchases its product components from multiple
sources.
The Company's manufacturing process is subject to the regulatory
requirements of the Federal Good Manufacturing Practice Regulations as
promulgated by the FDA. The Company conducts quality assurance audits
throughout the entire manufacturing process to ensure that all medical
products comply with the applicable government regulations.
Marketing and Sales
The Company sells certain of its products to or through national or
international distributors which include affiliates of major healthcare
corporations. In May 1991, the Company entered into a new distribution
agreement with J & J, under which J & J is granted the exclusive right to sell
the Company's bipolar electrosurgical systems, irrigation system, C/T Sets,
titanium surgical mesh and other products developed by the Company in the
field of neurosurgery through December 31, 1998.
Under the terms of the distribution agreement, J & J is required to
purchase no less than $1,100,000 in 1994 and subsequent years. For the 1996,
1995 and 1994 fiscal years, the Company had sales to J & J of $3,055,531,
$2,042,990, and $3,246,858, respectively. Orders are generally filled on a
current basis in each calendar year.
Approximately 89% of the Company's sales were derived from sales
to J & J in fiscal 1996 and approximately 76% and 90% of sales were made
to J & J in fiscal 1995 and 1994, respectively. Under the terms of a
development agreement with J & J, the Company has agreed to pay J & J
through December 31, 1998 a royalty of 2-1/2% of the net sales of the high
power bipolar electrosurgical system and 2% of the net sales of the C/T Sets
outside of the field of neurosurgery.
In July 1992, the Company entered into an exclusive five year
distribution agreement with Boston Scientific Corporation for the sale of a
bipolar electrosurgical coagulator specifically designed for use in the fields
of gastroenterology and endoscopy for hospital, outpatient clinics and office
based procedures involving flexible endoscopy. The agreement requires
Boston Scientific Corporation, to make minimum purchases of the product on
an annual basis in order to maintain its exclusivity in their field of
interest.
The Company currently has a nonexclusive distribution agreement
with CDX, Inc. to sell the Company's disposable CPR mask system. This
agreement, which was entered into in August, 1992 for a term of ten years,
was changed from an exclusive distribution agreement to a nonexclusive
distribution agreement in March, 1996.
In the first quarter of 1995, the Company entered into a distribution
agreement with Padgett Instruments, Inc. for a bipolar coagulation and cutting
system to be sold in the plastic and reconstructive surgery market. The
Company now has orders for both generators and accessory products under
this agreement.
While the Company's products are sold in foreign markets by J & J
and Boston Scientific Corporation, the Company is not aware of the amount
of products which are sold in those markets. Prior to sales in certain foreign
markets, the Company will need to comply with applicable foreign government
regulations.
The Company currently sells the surgical magnifying loupes and the
surgical stool through the members of the Association of Neurosurgical
Distributors.
The Company's business is not affected to any material extent by
seasonal factors.
Competition
The Company is a leading manufacturer of bipolar electrosurgical
systems, and its systems, because of their unique circuitry and patented wave
form, are distinguished from other bipolar electrosurgical systems. In the
neurosurgery market, the Company believes that it is the principal
manufacturer of bipolar electrosurgical systems. In other medical areas, the
Company's products will compete with monopolar electrosurgical systems, as
well as products based on other technologies, such as laser devices. The
Company believes that its bipolar electrosurgical products offer enhanced
capabilities and safety advantages as compared to monopolar electrosurgical
systems and laser devices.
The principal manufacturers of monopolar electrosurgical systems
(currently the standard electrosurgical device used in the general surgery
fields) are Valleylab, an affiliate of Pfizer, Inc., and Birtcher Medical
Systems, Inc. An ultrasound device is sold by Valleylab and laser devices are
sold by companies such as Surgical Laser Technology.
A number of major medical product suppliers, including U.S. Surgical
Corp., Ethicon, Inc. (a subsidiary of Johnson & Johnson), and Bard
Endoscopic (a division of C.R. Bard) are selling or preparing to sell
laparoscopic or endoscopic instruments for use with monopolar electrosurgical
systems or other modalities. Certain of the laser surgical devices currently
marketed by such firms as Surgical Laser Technology and Laserscope are also
being used for general surgery.
While there are currently several manufacturers of CPR masks, the
Company believes that its CPR Mask made of silicone, which folds into a
pocket portable size, yet deploys instantly for emergency use, offers
advantages over other products.
Research and Development
For the 1996, 1995, and 1994 fiscal years, the Company expended
$87,536, $125,775 and $95,609, respectively, for research and development.
The Company anticipates that it will continue to incur research and develop-
ment costs in connection with development of products.
In the past, the Company's research and development was conducted
internally as well as subcontracted to third parties. As a result of the
acquisition of Diversified, the Company anticipates that its future research and
development will be conducted internally. Clinical testing of the products is
conducted by physicians, including, Dr. Leonard I. Malis, a principal shareho-
lder and director of the Company.
In the 1997 fiscal year, the Company anticipates that it will fund all
its research and development with current assets and revenues from
operations.
Government Regulation
The marketing and sale of the Company's products is governed by the
Federal Food, Drug and Cosmetic Act (the "Act") administered by the FDA,
as well as varying degrees of regulation by a number of foreign governmental
agencies. The Act requires certain clearances from the FDA before medical
devices can be marketed.
All medical devices introduced into the market since 1976, which
include substantially all of the Company's products, are required by the FDA
as a condition of sale and marketing to secure either a 510(k) premarket
notification clearance or an approved Premarket Approval application
("PMA"). A 510(k) premarket notification clearance indicates FDA
agreement with an applicant's determination that the product for which
clearance has been sought is substantially equivalent to another medical device
that was on the market prior to 1976 or that has received 510(k) premarketing
notification clearance. In general, the process of obtaining a 510(k) clearance
typically takes several months and involves the submission of limited clinical
data and supporting information while the PMA process typically will last
more than a year and requires the submission of significant quantities of
clinical data and manufacturing information.
To comply with the FDA regulations, the Company incurs substantial
costs relating to laboratory and clinical testing of new and existing products
and the preparation and filing of documents in formats required by the FDA.
From time to time, the Company may also encounter delays in bringing new
or existing devices to market as a result of being required by the FDA and
foreign governmental authorities to conduct and document additional
investigations of product safety and effectiveness.
The Company believes that it is in material compliance with
regulations promulgated by the FDA and foreign governmental authorities,
and that such compliance has been and is anticipated to be without adverse
effect on its business.
Patents and Trademarks
The Company owns two principal United States patents for bipolar
electrosurgery, one relating to the circuitry employed by the Company's bipolar
electrosurgical systems and the other relating to two products under
development. The patent for circuitry, which was first granted in 1986 and
subsequently expanded upon in June 1994, covers 92 claims and is an
important aspect of the Company's bipolar electrosurgical systems.
In November 1995, the Company was granted a United States patent
for its CPR mask system. The Company's practice and experience is to apply
for patents which are important to the development or sale of a product.
Dr. Leonard Malis has entered into an agreement with the Company
to license the "MALIS" trademark to the Company, at no cost to the Company,
to the extent the name has not been licensed to Johnson & Johnson. The
Company has also registered or is in this process of registering other
trademarks.
Employees
At September 30, 1996, the Company and its subsidiaries had 33
full-time employees, including executive officers. The Company from time to
time retains part-time employees, engineering consultants, scientists and other
consultants. All full-time employees participate in the Company's health
benefit plan.
None of the Company's employees are represented by a union or
covered by a collective bargaining agreement. The Company considers its
relationship with its employees to be satisfactory.
Item 2. PROPERTIES.
The Company currently leases approximately 4,200 square feet of
office and warehouse space at a base monthly rent of $4,362 (with increases
based on increases in the consumer price index) in an office building in Oaks,
Pennsylvania, approximately 12 miles northwest of Philadelphia,
Pennsylvania. The current lease is for a term of five years ending on June 30,
2000. On August 31, 1994, the Company acquired a building with
approximately 15,000 square feet of manufacturing and warehouse space in
Philadelphia, Pennsylvania.
Item 3. LEGAL PROCEEDINGS.
As of September 30, 1996, there are no material pending legal
proceedings to which the Company is a party or to which any of its property
is the subject.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS.
No matters were submitted to a vote of the shareholders during the
fourth quarter of fiscal year 1996.
PART II
Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY
AND RELATED STOCKHOLDER MATTERS.
The Company's Common Stock is quoted on the Boston Stock
Exchange under the symbol VLF, and traded in the over-the-counter market,
and is included in the National Association of Securities Dealers Automated
Quotation (NASDAQ) System - Small Cap Issues under the symbol VLFG.
The table below sets forth the range of high and low closing bid quotations per
share of Common Stock as reported on the NASDAQ System. Quotations
represent prices between dealers and do not necessarily represent actual
transactions. None of the prices shown reflect retail mark-ups, mark-downs,
or commissions.
COMMON STOCK High-Bid Low-Bid
Fiscal 1995:
First Quarter .......................... $3 $2
Second Quarter.......................... 3 1/16 1 13/16
Third Quarter........................... 4 5/8 2 15/16
Fourth Quarter.......................... 4 2
Fiscal 1996:
First Quarter........................... $4 $2
Second Quarter.......................... 2 1 7/16
Third Quarter........................... 3 1 13/16
Fourth Quarter.......................... 3 5/16 1 7/8
At December 17, 1996, the Company had 123 shareholders of record.
The Company believes that there are in excess of 1,000 beneficial
shareholders of its Common Stock.
The Company has not paid any dividends to date, nor does it expect
to do so in the foreseeable future.
Item 6. SELECTED FINANCIAL DATA
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
Statement of Operations Data: 1996 1995 1994(1)(2) 1993 1992
Net Sales $3,424,589 $2,688,427 $3,587,379 $2,401,651 $1,531,102
Income (loss) from Operations (96,285) (368,415) 694,159 249,003 (178,304)
Net Income (loss) $(75,116) ($215,574) $547,615 $234,160 $(153,429)
======== ========== ======== ======= ========
Primary Earnings (loss) per share $(.01) $(.03) $.07 $.03 $(.02)
====== ====== ===== ===== ======
Fully Diluted Earnings (loss)
per share $(.01) $(.03) $.07 $.03 $(.02)
====== ====== ===== ===== ======
Balance Sheet Data:
At September 30,
1996 1995 1994 1993 1992
Current Assets $2,987,502 $3,052,414 $3,429,443 $3,007,457 $2,393,408
Total Assets 4,217,958 4,379,866 4,884,525 3,754,205 3,158,793
Current Liabilities 164,595 256,123 353,891 220,629 109,090
Long Term Liabilities 4,736 0 170,775 0 903
Retained Earnings (deficit) (3,071) 72,045 287,619 (259,996) (494,156)
Stockholders' Equity 4,048,627 4,123,743 4,359,859 3,553,576 3,048,800
(1) On August 31, 1994, the Company acquired Diversified Electronic Corporation
pursuant to an Agreement and Plan of Merger. After
September 1, 1994, the operations of Diversified Electronic Corporation
were conducted by the Company's Diversified Electronics
Company, Inc., wholly owned subsidiary. The results of operations of
Diversified Electronics Company, Inc. from September 1, 1994
are included in the results of operations of the Company.
(2) See Note 2 to the Company's financial statements (commencing on page F-1,
hereto) for a summary of the unaudited proforma results
of operations of the Company and Diversified Electronic Corporation had
the business combination occurred on October 1, 1993.
Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Results of Operations
1996 and 1995 Fiscal Year Compared
Sales of $3,424,589 for 1996 were 27% greater than sales for 1995.
The sales increase primarily resulted from increased sales to Johnson &
Johnson Professional, Inc., ("J&J"), the Company's principal customer with
whom the Company has an existing distribution agreement. In 1996, J&J
accounted for 89% of the Company's sales, as compared to 76% and 90% of
the sales in 1995 and 1994, respectively. The sales gains reflect increased
shipments of the Company's surgical generators.
Approximately 54% of the Company's 1996 sales related to sales
of the bipolar electrosurgical and irrigation systems as compared to
approximately 69% and 67% of the sales in fiscal 1995 and 1994,
respectively. Sales of C/T Sets in 1996 accounted for approximately 35%
of the Company's sales in 1996 and approximately 28% and 27% in 1995 and
1994, respectively. DEC accounted for approximately 8% of the Company's
sales in 1996 as compared to 11% in 1995.
The Company's gross profit margin was 46% for 1996 as compared
to gross profit margin of 47% and 55% for 1995 and 1994, respectively.
Selling, general and administrative expenses increased by 7% in 1996 as
compared to the amounts for 1995. Selling, general and administrative
expenses were impacted by costs related to the assimilation of Diversified
Electronic Corporation as a result of the August 1994 merger. Research and
development expenses decreased by 30% to $87,536 in 1996, reflecting the
completion of development of new generators in 1995.
In March 1996, the Company modified its distribution agreement for
the CPR mask system with CDX Corporation from an exclusive distribution
agreement to a nonexclusive agreement. The Company also commenced
marketing the CPR mask system directly with other customers and
distributors.
The Company had a loss from operations of $96,285 for 1996 which
was 74% less than the loss from operations of $368,415 for 1995. The
Company had a loss before taxes of $88,095 in 1996 as compared to a loss
before taxes of $363,965 in 1995. The Company's tax benefit was $12,979
in 1996 as compared to $148,391 in 1995.
As a result of the foregoing, the Company had a net loss of $75,116
in 1996 as compared to a net loss of $215,574 for 1995. Primary and fully
diluted loss per share was $.01 for 1996 compared to loss per share of $.03 for
1995.
1995 and 1994 Fiscal Years Compared
Sales of $2,688,427 for 1995 were 25% less than sales for 1994. The
sales decrease primarily resulted from lower sales to Johnson & Johnson
Professional, Inc., ("J & J"), the Company's principal customer with whom the
Company has an existing distribution agreement. Sales were also affected by
delays in the introduction of the Company's bipolar electrosurgical systems
and instrumentation for use in the fields of gynecology and urology and delays
in finalizing a design modification to the CPR Mask System.
In 1995, the Company completed the development of two new bipolar
neurosurgical generators for J&J, a new bipolar endoscopic generator for the
Microvasive division of Boston Scientific Corporation, a bipolar generator for
plastic/reconstructive surgery for Padgett Instruments, Inc., two bipolar
generators for gynecology procedures, a bipolar generator for urology
procedures and improved bipolar loop electrodes. As a result of the
development of the new generators for J & J, sales of the existing generators,
which are being replaced by the new generators, were at low levels as J & J
reduced its inventories. Sales of the new bipolar endoscopic generator and the
bipolar generator for plastic/reconstructive surgery are expected to commence
in the second quarter of fiscal 1996 through existing distribution agreements.
In 1995, J & J accounted for 76% of the Company's sales, as
compared to 90% and 94% of the sales in 1994 and 1993, respectively. Sales
for 1995 included sales of the Company's Diversified Electronics Company,
Inc., ("DEC") subsidiary for the entire year and sales in 1994 included sales
of DEC from September 1, 1994 to September 30, 1994 (see "Acquisition of
Diversified" below).
Approximately 69% of the Company's 1995 sales related to sales of
the bipolar electrosurgical and irrigation systems as compared to
approximately 67% and 66% of the sales in fiscal 1994 and 1993,
respectively. Sales of C/T Sets in 1995 accounted for approximately 28% of
the Company's sales in 1995 and approximately 27% and 25% in 1994 and
1993, respectively. DEC accounted for approximately 11% of the Company's
sales in 1995. DEC's 1995 sales reflect the termination of a manufacturing
relationship with an outside customer, which historically accounted for
approximately $200,000 in annual sales, as DEC concentrated its efforts on
completing the development of several of the Company's bipolar generators
and streamlining the manufacturing of the Company's bipolar generators.
The Company's gross profit margin was 47% for 1995 as compared
to gross profit margin of 55% and 61% for 1994 and 1993, respectively, while
selling, general and administrative expenses increased by 26% in 1995 as
compared to the amounts for 1994. The decrease in gross profit margins and
the increase in selling, general and administrative expenses was primarily due
to costs associated with the assimilation of Diversified Electronic Corporation
as a result of the August 1994 merger and the ramp-up of bipolar
electrosurgical systems and new disposable products in the fields of urology,
gynecology, plastic/reconstructive surgery and orthopedics.
The Company had a loss from operations of $368,415 for 1995 as
compared to income from operations of $694,159 for 1994.
The Company had a loss before taxes of $363,965 in 1995 as
compared to income before taxes of $711,530 in 1994. The Company's tax
benefit was $148,391 in 1995. The Company's provision for income taxes net
of its credit of $138,167 for net operating loss carry forward was $163,915 in
1994.
As result of the foregoing, the Company had a net loss of $215,574
in 1995 as compared to a net income of $547,615 for 1994. Primary and fully
diluted loss per share was $.03 for 1995 compared to earnings per share of
$.07 for 1994.
Liquidity and Capital Resources
The primary measures of the Company's liquidity are cash balances
(including short-term investments), accounts receivable and inventory
balances, as well as its borrowing ability. During 1996, the Company's
working capital increased by $26,616 to $2,822,907.
For the 1996 fiscal year, the Company used net cash of $126,102 in
operating activities which reflects an increase in accounts receivable and
inventory and prepaid items of $166,636, $239,432 and $27,014 respectively,
less the net loss from operations as adjusted for noncash items of $67,159, a
decrease in recoverable income taxes of $157,482 and an increase of accounts
payable of $89,150. The increase in inventory and accounts receivable was primarily due
to higher sales levels.
Investing activities for 1996 used $45,693 for an increase in
intangible assets of $14,508 and for the purchase of equipment in the amount
of $31,185. Financing activities used $180,678 for the payment of a note
payable originally issued in connection with the merger of Diversified
Electronic Corporation into the Company. Cash decreased by $352,473 in
1996 leaving a balance of $162,761 in the Company's cash and cash
equivalents at September 30, 1996.
For the 1995 fiscal year, the Company used net cash of $44,448 in
operating activities representing the net loss from operations as adjusted for
noncash items of $72,372, a decrease in accounts payable and accrued
expenses of $145,159, an increase in recoverable income taxes and deferred
income tax benefit of $258,375, and a decrease in income taxes payable of
$86,099, less a decrease in accounts receivable, and inventory of $480,514
and $43,340 respectively. The decrease in inventory and accounts receivable
was primarily due to lower sales volume.
Investing activities for 1995 used a total of $42,501, representing
$945 for the increase in intangible assets related to patents, and $45,556
representing purchases of property, plant and equipment. Financing activities
for 1995 used $57,827 representing a reduction in notes payable of $37,285
and the repurchase of 10,000 shares of common stock for $20,542. Cash
decreased by $144,776 in 1995 leaving a balance of $515,234 in the
Company's cash and cash equivalents at September 30, 1995.
On March 1, 1996, the Company and Bernard H. Shuman, a director
of the Company, modified the payments terms of a note originally issued in
connection with the Company's merger with Diversified Electronic
Corporation in August 1994, and which was due on March 1, 1996. Pursuant
to the modification, the Company paid Mr. Shuman $100,000 to reduce the
principal balance for the note on March 1, 1996, $15,000 in April, 1996 and
$70,000 on August 1, 1996. On August 1, 1996, the note was canceled.
The Company has a line of credit of $750,000 with Meridian Bank
which expires January 31, 1997 and calls for interest to be charged at the
bank's national commercial rate. The credit accommodation is unsecured. At
September 30, 1996, there was no outstanding balances on this line.
At September 30, 1996, the Company's total debt was $169,331 and
the ratio of total debt to total equity was 4%. The Company believes it has
available all funds needed for operations, research and development and
capital expenditures as they may arise in the future. However, should it be
necessary, the Company believes it could borrow adequate funds at
competitive rates and terms.
Acquisition of Diversified
On August 31, 1994, the Company acquired Diversified Electronic
Corporation ("Diversified") pursuant to a Merger Agreement, in which the
Company was the surviving corporation. After the merger, Diversified
Electronics Company, Inc., a wholly owned subsidiary of the Company,
conducted the operations of Diversified. In the Merger Agreement, the
Company issued the following consideration: (i) cash in the amount of
$161,500; (ii) a noninterest bearing note in the amount of $185,000 payable
on March 1, 1996; (iii) a noninterest bearing note in the amount of $47,188
which was paid upon the collection of certain accounts receivable of
Diversified; and (iv) 139,334 shares of unregistered common stock of the
Company. The cash portion of the consideration was funded with the
Company's available cash on hand. The assets of Diversified consisted
primarily of equipment, fixtures, inventory, and intellectual property. Prior
to the merger, Diversified Electronics Company, Inc., a wholly owned subsidiary
of the Company, acquired the real property and building, which constituted
Diversified's manufacturing facility, for $95,000 in cash.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
A. Quarterly Results of Operations.
Not applicable.
B. Financial Statements and Financial Statement Schedules.
See Index to Financial Statements and Financial Statement Schedules
on page F-1 herein.
Item 9. DISAGREEMENTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE.
Not applicable.
PART III
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE
REGISTRANT.
The information concerning directors and officers called for by Item
10 of Form 10-K will be set forth either: (i) in the Company's Definitive Proxy
Statement for its Annual Meeting of Stockholders, or (ii) in an amendment to
this Annual Report on Form 10-K, which in either case will be filed within 120
days after the end of the fiscal year covered by this Annual Report on Form
10-K, and is incorporated herein by reference.
Item 11. EXECUTIVE COMPENSATION.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT.
Item 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS.
The information called for by Items 11, 12 and 13 of Form 10-K will
be set forth either: (i) in the Company's Definitive Proxy Statement for its
Annual Meeting of Stockholders, or (ii) in an amendment to this Annual
Report on Form 10-K, which in either case will be filed within 120 days after
the end of the fiscal year covered by this Annual Report on Form 10-K, and is
incorporated herein by reference.
PART IV
Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
AND REPORTS ON FORM 8-K.
a. and d. Financial Statements and Financial Statement
Schedules.
See Index to Financial Statements and Financial Statement
Schedules on Page F-1, herein.
b. Reports on Form 8-K.
None.
c. Exhibits
The following is a list of exhibits filed as part of this annual report
on Form 10-K. Where so indicated by footnote, exhibits which were
previously filed are incorporated by reference. For exhibits incorporated by
reference, the location of the exhibit in the previous filing is indicated in
parentheses.
(2) Agreement and Plan of Merger.
(a) Agreement and Plan of Merger between Valley Forge
Scientific Corp. and Diversified Electronic Corporation dated August 31,
1994. (4)
(3) Articles of Incorporation and By-Laws.
(a) Articles of Incorporation, as amended - (1) (Exhibit
3(a)).
(b) By-Laws of the Company, as amended - (1) (Exhibit
3(b)).
(4) Instruments defining the Rights of Security Holders, including
Indentures.
(a) Form of Common Stock Certificate - (1) (Exhibit
4(a)).
(10) Material Contracts.
(a) Non-Qualified Employee Stock Option Plan - (1)
(Exhibit 10(a)).
(b) Assignment of Know-How Agreement, dated June
30, 1989 - (1) (Exhibit 10(g)).
(c) Assignment of Patents - Bipolar Electrosurgical
Systems, June 30, 1989 - (1) (Exhibit 10(h)).
(d) Assignment of Patents - Binocular Magnification
System, June 30, 1989 -(1) (Exhibit 10(i)).
(e) Assignment of Malis tradename, dated June 30,
1989 - (1) (Exhibit 10(j)).
(f) 401(k) and Profit-Sharing Plan - (2) (Exhibit 10(x)).
(g) Distribution Agreement between Codman &
Shurtleff, Inc. and the Company (3)(Exhibit 10(b)).
(h) Amended and Restated Registration Rights
Agreement, dated April 3, 1991 - (3)(Exhibit
10(g)).
(i) Promissory Note from Thomas J. Gilloway to the
Company. (5)(Exhibit 10(1))
(j) Promissory Note from Jerry L. Malis to the
Company. (6) (Exhibit 10(k))
(k) Promissory Note from the Company to Bernard H.
Shuman. (6) (Exhibit 10(l))
(l) Employment Agreement Jerry L. Malis. (6) (Exhibit
10(m))
(m) Employment Agreement Thomas J. Gilloway. (6)
(Exhibit 10(n))
(n) Employment Agreement Bernard H. Shuman. (6)
(Exhibit 10(o))
(o) Registration Rights Agreement between the
Company and Bernard H. Shuman (6) (Exhibit
10(p))
(p) Commercial Lease Agreement between GMM
Associates and the Company dated July 1, 1995 (7)
(Exhibit 10(p))
(21) Subsidiaries of Registrant
(1) Previously filed with the Registration Statement of the
Company on Form S-18, Registration No. 33-31008-NY,
and incorporated herein by reference.
(2) Previously filed with the Registration Statement of the
Company on Form S-18, Registration No. 33-35668-NY,
and incorporated herein by reference.
(3) Previously filed with the Registration Statement of the
Company on Form S-1, Registration No. 33-40545, and
incorporated herein by reference.
(4) Previously filed with the Company's Form 8-K
dated August 31, 1994, and incorporated herein by
reference.
(5) Previously filed with the Company's Form 10-K for
the year ended September 30, 1993, and
incorporated herein by reference.
(6) Previously filed with the Company's Form 10-K for the year
ended September 30, 1994, and incorporated herein by
reference.
(7) Previously filed with the Company's Form 10-K for the year
ended September 30, 1995, and incorporated herein by
reference.
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized on this 26th day
of December, 1996.
VALLEY FORGE SCIENTIFIC CORP.
By: /s/ Jerry L. Malis
Jerry L. Malis, President
Pursuant to the requirements of the Securities Act of 1934, this report has
been signed by the following persons on behalf of the Registrant and in the
capacities and on the dates indicated.
Signature Title Date
/s/ Jerry L. Malis Chairman of the Board, December 26, 1996
Jerry L. Malis President (chief executive
officer and principal
financial and accounting
officer)
/s/ Thomas J. Gilloway Executive Vice President, December 26, 1996
Thomas J. Gilloway Secretary, Treasurer, Director
/s/ Leonard I. Malis Director
Leonard I. Malis December 26, 1996
/s/ Bruce A. Murray Director December 26, 1996
Bruce A. Murray
/s/ Bernard H. Shuman Vice President, Director December 26, 1996
Bernard H. Shuman
VALLEY FORGE SCIENTIFIC CORP.
Index to Financial Statements and Financial Statement Schedules
Independent Auditor's Report F-2
Balance Sheets - September 30, 1996 and 1995 F-3
Statements of Operations - Years Ended September 30, 1996, 1995 F-4
and 1994
Statements of Stockholders' Equity - Years ended September 30, 1996, F-5
1995 and 1994
Statements of Cash Flows - Years ended September 30, 1996, 1995 and 1994 F-6
Notes to Financial Statements F-8
___________________
All other schedules for which provision is made in the applicable
accounting regulations of the Securities and Exchange Commission are not
required under the related instructions or are inapplicable, and therefore have
been omitted.
INDEPENDENT AUDITOR'S REPORT
The Board of Directors and Stockholders
Valley Forge Scientific Corp. and Subsidiaries
Oaks, Pennsylvania
We have audited the accompanying consolidated balance sheets of Valley Forge Scientific Corp. and
Subsidiaries as of September 30, 1996 and 1995 and the related consolidated statements of operations, stockholders'
equity and cash flows for each of the three years ended September 30, 1996. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing standards. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing the accounting principles and significant
estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the
financial position of Valley Forge Scientific Corp. and Subsidiaries as of September 30, 1996 and 1995, and the results
of operations and cash flows for each of the three years ended September 30, 1996, in conformity with generally accepted
accounting principles.
SAMUEL KLEIN AND COMPANY
Newark, New Jersey
December 6, 1996
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
BALANCE SHEETS
September 30,
ASSETS 1996 1995
Current Assets:
Cash and cash equivalents $ 162,761 $ 515,234
Accounts receivable, net 871,648 705,012
Inventory 1,687,797 1,448,365
Prepaid items and other current assets 87,258 60,244
Recoverable income taxes 12,889 170,371
Current portion of deferred income tax benefit 165,149 153,188
_________ _________
Total Current Assets 2,987,502 3,052,414
Property, Plant and Equipment, net of accumulated depreciation 303,414 324,296
Intangible Assets, net of accumulated amortization 922,670 998,370
Deferred Income Tax Benefit, net of current portion - 414
Other Assets 4,372 4,372
__________ __________
Total Assets $4,217,958 $4,379,866
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Current portion of notes payable $ - $ 180,678
Accounts payable and accrued expenses 164,595 75,445
__________ __________
Total Current Liabilities 164,595 256,123
Deferred Income Taxes Payable 4,736 -
__________ __________
Total Liabilities 169,331 256,123
__________ __________
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - -
Common stock (no par, 10,000,000 shares
authorized, 8,229,384 shares issued
and outstanding at September 30,
1996 and 1995) 4,051,698 4,051,698
Retained earnings (deficit) (3,071) 72,045
__________ _________
Total Stockholders' Equity 4,048,627 4,123,743
__________ _________
Total Liabilities and Stockholders' Equity $4,217,958 $4,379,866
========== =========
The accompanying notes are an integral part of these financial statements.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
STATEMENTS OF OPERATIONS
For the Years Ended September 30,
1996 1995* 1994*
Net Sales $3,424,589 $2,688,427 $3,587,379
Cost of Sales 1,840,130 1,431,466 1,619,863
_________ _________ _________
Gross Profit 1,584,459 1,256,961 1,967,516
_________ _________ _________
Other Costs:
Selling, general and administrative 1,503,000 1,409,246 1,128,996
Research and development 87,536 125,775 95,609
Amortization 90,208 90,355 48,752
_________ _________ _________
Total Other Costs 1,680,744 1,625,376 1,273,357
Income (loss) from Operations (96,285) (368,415) 694,159
Other Income (Expense):
Interest income (expense) 8,190 2,205 17,371
Gain on sale of equipment - 2,245 -
_________ ________ ________
Income (loss) before income taxes (88,095) (363,965) 711,530
Provision for (Benefit of) income taxes (12,979) (148,391) 163,915
_________ _________ _______
Net income (loss) $ (75,116) $ (215,574) $ 547,615
========= ========= =======
Earnings (Loss) per share:
Primary earnings (loss) per share of common stock $ (.01) $ (.03) $ .07
========= ========= =======
Fully diluted earnings (loss) per share $ (.01) $ (.03) $ .07
========= =========== =========
Primary common shares outstanding 8,269,203 8,318,675 8,204,289
Fully diluted common shares outstanding 8,308,428 8,318,675 8,204,289
* Restated and reclassified to conform to current year presentation.
The accompanying notes are an integral part of these financial statements.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED SEPTEMBER 30, 1996, 1995 AND 1994
Common Stock
No Par Value
___________________________ Retained Total
Number of Common Earnings Stockholders'
Shares Stock Amount (Deficit) Equity
_________ __________ __________ _________
Balances, September 30, 1993 8,100,050 $3,793,572 $ (259,996) $3,533,576
Issuance of Shares 139,334 278,668 - 278,668
Net Income for the Year
Ended September 30, 1994 - - 547,615 547,615
_________ _________ _______ _________
Balances, September 30, 1994 8,239,384 4,072,240 287,619 4,359,859
Retirement of Shares (10,000) (20,542) - (20,542)
Net Loss for the Year
Ended September 30, 1995 - - (215,574) (215,574)
_________ _________ __________ _________
Balances, September 30, 1995 8,229,384 $4,051,698 $ 72,045 $4,123,743
Net Loss for the Year
Ended September 30, 1996 - - (75,116) (75,116)
_________ _________ __________ __________
Balances, September 30, 1996 8,229,384 $4,051,698 $ (3,071) $4,048,627
========= ========= ========== ==========
The accompanying notes are an integral part of these financial statements.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
STATEMENTS OF CASH FLOWS
For the Years Ended September 30,
1996 1995 1994
____ ____ ____
Cash Flows from Operating Activities:
Net income (loss) $ (75,116) $(215,574) $ 547,615
Adjustments to reconcile net income (loss) to net
cash provided by (used in) operating activities:
Depreciation and amortization 142,275 143,202 81,046
Gain on disposition of assets ( 2,245)
Changes in assets and liabilities, net of
effect from:
(Increase) decrease in accounts receivable (166,636) 480,514 (343,184)
(Increase) decrease in inventory (239,432) 43,340 (151,187)
(Increase) decrease in recoverable income taxes 157,482 (170,371) -
Increase in deferred income tax benefit (11,547) (88,004) (65,598)
Increase (decrease) in accounts payable and
accrued expenses 89,150 (145,159) 9,343
Increase (decrease) in income taxes payable - (86,099) 49,658
Increase in deferred taxes payable 4,736 - -
Decrease in other assets - 425 350
Decrease (increase) in prepaid items and
other current assets (27,014) (4,477) 7,956
Net cash provided by (used in) _______ ________ _______
operating activities (126,102) (44,448) 135,999
_______ ________ _______
Cash Flows from Investing Activities:
Cost of acquisition net of cash acquired - - (256,500)
Increase in intangible assets (14,508) (945) (59,319)
Purchase of property, plant and equipment (31,185) (45,556) (110,540)
Proceeds from sale of equipment - 4,000 -
Net cash used in investing ________ ________ _________
activities (45,693) (42,501) (426,359)
________ ________ _________
Cash Flows from Financing Activities:
Net reduction in notes payable (180,678) (37,285) (68)
Purchase and retirement of common stock - (20,542) -
_________ ________ ________
Net cash used in financing activities (180,678) (57,827) (68)
_________ _________ _________
Net Decrease in Cash and Cash Equivalents (352,473) (144,776) (290,428)
Cash and Cash Equivalents, beginning of year 515,234 660,010 950,438
_______ _______ _______
Cash and Cash Equivalents, end of year $162,761 $ 515,234 $660,010
======= ======= =======
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
STATEMENTS OF CASH FLOWS
(Continued)
For the Years Ended September 30,
1996 1995 1994
____ ____ ____
Supplemental Disclosures of Cash Flow Information:
Cash paid during the year for:
Interest $ 14,225 $ - $ 4
====== ======== =========
Income taxes $ - $ 199,814 $ 178,030
====== ======== =========
Supplemental Disclosures of Noncash
Investing and Financing Activities:
Acquisition:
Fair value of assets acquired, other
than cash $ - $ - $1,175,115
Excess fair value of assets over
purchase price - - (394,843)
Notes payable issued - - (217,163)
Liabilities assumed - - (27,941)
Common stock issued - - (278,668)
_______ ________ _________
Cost of acquisition net of cash
acquired $ - $ - $ 256,500
======= ======== ========
The accompanying notes are an integral part of these financial statements.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Company
Valley Forge Scientific Corp. ("VFSC") was incorporated on March 27, 1980 in the Commonwealth
of Pennsylvania and is engaged in the business of developing, manufacturing and selling medical devices and products.
On August 18, 1994, VFSC formed a wholly-owned subsidiary, Diversified Electronics Company, Inc. ("DEC"), a
Pennsylvania corporation, in order to continue the operations of Diversified Electronic Corporation, a company which was
merged with and into VFSC on August 31, 1994 (See Acquisitions, Note 2). In January 1993, VFSC formed a wholly -
owned subsidiary, Valley Consumer Products, Inc. ("VCP"). During 1996, VCP commenced initial operations and
began marketing for the CPR mask system. Collectively, VFSC, DEC and VCP are referred to herein as the "Company".
Cash and Cash Equivalents
The Company considers cash equivalents to be all highly liquid investments with original maturities
of three months or less.
Principals of Consolidation and Basis of Presentation
The accompanying financial statements consolidate the accounts of the parent company and its wholly-owned subsidiaries.
All significant intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition
The Company currently sells its products to or through national or international distributors which include affiliates of
major health care corporations. A significant part of the Company's sales are made pursuant to a distribution agreement
in the field of neurosurgery effective through December 31, 1998. Revenues from sales are recorded on the accrual basis
of accounting, when goods are shipped or when services are provided.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those estimates.
Inventory
Inventory is stated at the lower of cost, determined by the moving average cost method, or market.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. Depreciation is computed by the straight-line method over the
estimated useful lives of the assets, which vary from three to forty years. Leasehold improvements
are being amortized over the related lease term or estimated useful lives, whichever is shorter.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(Continued)
Property, Plant and Equipment (continued)
Upon retirement or other disposition of these assets, the cost and related accumulated depreciation are removed from the
accounts and the resulting gains or losses are reflected in the results of operations. Routine maintenance and repairs are
charged to expense as incurred.
Intangible Assets
Intangible assets, consisting of patents, licensing agreements, proprietary know-how, cost of acquisition and goodwill are
amortized to operations under the straight-line method over their estimated useful lives or statutory lives, whichever is
shorter. Goodwill representing the excess of the purchase price paid over the fair market value of net assets acquired is
being amortized over 20 years. Acquisition costs have been capitalized and are being amortized over 5 years.
Research and Development
Costs associated with development of new products are charged to operations as incurred.
Earnings per Share
Primary earnings per common and common equivalent share are computed on the basis of the weighted average number
of common shares outstanding during each year and include shares assumed issued on the exercise of all common stock
equivalents, such as, dilutive stock options and warrants and the purchase of treasury stock with the proceeds at the average
market price for the period. Fully diluted earnings per share assumes the exercise of all dilutive common stock equivalents
and all other potentially dilutive securities and the purchase of treasury stock, at the higher of the market price at the end
of the year or the average market price during the year.
Income Taxes
Effective October 1, 1993, the Company adopted the provisions of Statement of Financial Accounting Standards No. 109,
"Accounting for Income taxes" ("SFAS 109"). The adoption of SFAS 109 changed the Company's method of accounting
for income taxes from the deferred method (APB 11) to an asset and liability approach. SFAS 109 requires the recognition
of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the
financial statements or tax returns. Under this method, deferred tax liabilities and assets are
determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities
using enacted tax rates in effect in the years in which the differences are expected to reverse. Valuation allowances are
established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company
determined that the cumulative effect of implementation of SFAS 109 was immaterial.
Reclassifications
Certain reclassifications have been made to the prior year balances to conform to the current year's
presentation.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
2. ACQUISITIONS
Pursuant to the terms of an agreement and plan of merger dated August 31, 1994 and an agreement for the acquisition of
real estate, the Company acquired Diversified Electronic Corporation ("Diversified"), a specialty electronics manufacturer
with whom the Company had contracted since its inception in 1980 to provide the manufacturing and engineering services
for the Company's electrosurgical generators. The acquisition is accounted for as a purchase. The aggregate purchase
price of $752,331 was comprised of the following consideration: (i) cash in the amount of $256,500; (ii) a non-interest
bearing note in the amount of $185,000, discounted to present value of $169,975, payable on March 1, 1996; (iii) a non-interest
bearing note in the amount of $47,188, payable upon the collection of certain accounts receivable of Diversified
which occurred during September and October 1994; and (iv) 139,334 shares of unregistered
common stock of the Company (estimated fair value at August 31, 1994 of $278,668, given the restricted nature of the
shares).
The assets of Diversified consisted primarily of real estate, equipment, fixtures, inventory, and intellectual property. The
allocation of the purchase price to the fair value of the net assets acquired from Diversified was based
upon appraisal reports which stated the fair market value of the net assets acquired at $1,147,169. Current
applicable accounting standards require that the excess of the fair value of the net assets acquired over the purchase price
shall reduce the values otherwise assignable to non-current assets acquired by a proportionate part of the excess in
determining their assigned values.
In addition, on August 31, 1994, the Company transferred the net assets of Diversified into its newly
formed subsidiary DEC to conduct the former operations of Diversified after the merger. The financial statements
include the results of operations of DEC since September 1, 1994.
The following summarizes the unaudited proforma results of operations for the year ended September
30, 1994 of the Company and Diversified had the business combination occurred on October 1, 1993.
Sales $4,100,339
Income from operations 738,224
Income before income taxes 759,560
Provision for income taxes net of
extraordinary credit for loss carryforward 178,399
Net income 581,161
Primary and Fully Diluted
Earnings per share $.07
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
3. ACCOUNTS RECEIVABLE
Accounts receivable is comprised of the following at September 30,
1996 1995
____ ____
Accounts receivable $1,105,255 $ 870,127
Less: Allowance for doubtful accounts
and contractual allowances 233,607 165,115
_________ _______
$ 871,648 $ 705,012
========= =======
4. INVENTORY
Inventory consists of the following:
September 30,
1996 1995
____ ____
Finished goods $ 34,279 $ 50,021
Work-in-process 1,129,495 906,306
Materials and parts 524,023 492,038
_________ _________
$1,687,797 $1,448,365
========= =========
5. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment consist of the following:
September 30,
1996 1995
____ ____
Land $ 11,953 $ 11,953
Building and improvements 81,332 77,919
Furniture and fixtures 15,369 12,493
Laboratory equipment 359,062 337,214
Office equipment 94,655 91,607
Leasehold improvements 9,413 9,413
_______ _______
571,784 540,599
Less: Accumulated depreciation
and amortization 268,370 216,303
_______ _______
$303,414 $324,296
======= =======
Depreciation is reflected in both cost of sales and selling, general and administrative expenses. Total
depreciation for the years ended September 30, 1996, 1995 and 1994 is $52,067, $53,036 and $32,294, respectively.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
6. INTANGIBLE ASSETS
Intangible assets consist of the following:
September 30,
1996 1995
Patents/trademarks/licensing ____ ____
agreements $ 546,859 $532,351
Proprietary know-how 452,354 452,354
Acquisition costs 55,969 55,969
Excess of purchase price over net
assets acquired in connection with
the acquisition of Technical Medical Industries 351,123 351,123
_________ _________
1,406,305 1,391,797
Less: Accumulated amortization 483,635 393,427
_________ _________
$ 922,670 $ 998,370
========= =========
7. RELATED PARTY TRANSACTIONS
On May 24, 1994, Jerry L. Malis, a principal shareholder, director and officer of the Company
borrowed $17,500 from the Company. The note is payable on demand and is secured by 5,833 shares of common stock of
the Company, and has a stated rate of interest at 4.83%, the then current "applicable federal rate" as set forth under the
Internal Revenue Code. On January 30, 1995 Jerry L. Malis borrowed an additional $5,320 from the Company.
The balance of the note and loan including accrued interest is reflected in other current assets and as
of September 30, 1996 and 1995 was $24,925 and $24,012, respectively.
8. NOTES PAYABLE
In connection with the Company's 1994 acquisition of Diversified, the Company issued two
promissory notes to the sole shareholder of Diversified who is a current officer, director and shareholder of the Company. Notes
payable consist of the following:
September 30,
1996 1995
Officer, director and shareholder - unsecured, ____ ____
due on March 1, 1996 with interest imputed
at 5.85% per annum (net of unamortized
interest of $4,322 at September 30, 1995) $ - $ 180,678
_______ _______
- 180,678
Less: Current portion - 180,678
______ _______
$ - $ -
======= =======
On March 1, 1996, the Company modified the payment terms of the note. Pursuant to the
modification, the Company paid $100,000 on March 1, 1996, $15,000 on April 11, 1996 and the remaining $70,000 on August
1, 1996.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
8. NOTES PAYABLE (Continued)
The Company has a line of credit of $750,000 with Meridian Bank which expires January 31, 1997
and calls for interest to be charged equal to the bank's national commercial rate. The credit accommodation is unsecured.
At September 30, 1996 and 1995 there were no outstanding balances on this line.
9. COMMITMENTS AND CONTINGENCIES
The Company is subject to litigation arising from the normal course of business. In management's
opinion, any such contingencies are covered under its existing insurance policies or do not materially affect the
Company's financial position.
The Company is subject to regulatory requirements throughout the world. In the normal course of
business, these regulatory agencies may require companies in the medical industry to change their products or
operating procedures, which could affect the Company. The Company regularly incurs expenses to comply with these procedures
and may be required to incur additional expenses. Management is not able to estimate any additional expenditure outside
the normal course of operations which will be incurred by the Company in future periods in order to comply with these
regulations.
Employment Agreements
On June 30, 1989, the Company entered into employment agreements with Jerry L. Malis, President
and Thomas J. Gilloway, Executive Vice President, for terms of five years which expired on June 30, 1994. The
agreements, as amended, provided for annual salaries to Mr. Malis and Mr. Gilloway of $140,360 and $118,580,
respectively.
Effective July 1, 1994, the Company entered into new employment agreements with Jerry L. Malis
and Thomas J. Gilloway, for terms of 63 months. The agreements provide for annual base salaries to Mr. Malis and
Mr. Gilloway of $148,720 and $126,940, respectively, with annual base salary increases at 10% commencing October
1, 1994. In addition the agreements provide that Messrs. Malis and Gilloway may each receive such other cash and stock
bonuses and benefits as may be determined from time to time by the Board of Directors. For the year ended September
30, 1996, the officers have waived their right to the 10% increase of base salary for that year. The base salary for Jerry L.
Malis and Thomas J. Gilloway for the years ended September 30, 1996 and 1995 were $163,592 and $139,634,
respectively.
On August 31, 1994, pursuant to the merger agreement with Diversified, the Company entered into
an employment agreement with Bernard H. Shuman, the former President of Diversified and a current Vice President
of the Company, for a term of 59 months commencing September 1, 1994. The agreement provides for a salary of
$50,000 per annum through July 31, 1995 and thereafter at $105,000 per annum through July 31, 1999. In addition, the
agreement provides that Mr. Shuman may receive such other compensation and benefits as the Board of Directors of the
Company may decide. The employment agreement may be terminated for cause. The base salary for Bernard H. Shuman
for the years ended September 30, 1996, 1995 and 1994 were $105,000, $59,170 and $4,167, respectively.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
9. COMMITMENTS AND CONTINGENCIES (Continued)
401(k) Plan and Profit Sharing Plan
The Company's 401(k) Plan and Profit Sharing Plan covers full-time employees who have attained
the age of 21 and have completed at least one year of service with the Company. Under the 401(k) Plan, an employee may
contribute an amount up to 25% of his compensation to the 401(k) Plan on a pre-tax basis not to exceed $9,240 per year
(as adjusted for cost of living increase). Amounts contributed to the 401(k) Plan are nonforfeitable.
Under the Profit Sharing Plan, a participant in the plan participates in the Company's contributions
to the Plan as of December 31 in any year, with allocations to individual accounts based on annual compensation. An
employee does not fully vest in an interest in the plan until completion of three years of employment. The Board of
Directors determines the Company's contributions to the plan on a discretionary basis. The Company has not made any
contributions to date.
Stock Option Plan
On July 6, 1988, the Company adopted a non-qualified employee stock option plan (the "Plan")
pursuant to which 500,000 shares of Common Stock have been reserved for issuance to employees, officers, directors or
consultants of the Company. Options granted pursuant to this plan will be non-transferrable and expire if not exercised after ten
years. Options may be granted in such amounts and at such prices as determined by the Board of Directors, but the price
per share shall not be less than the fair market value of the Company's Common Stock.
On October 24, 1994, the Company granted to employees and a board member stock options to
purchase 20,000 shares of common stock pursuant to the plan, at $2.50 per share (the closing bid price on the NASDAQ
small-cap market on October 24, 1994). Options granted pursuant to this plan expire if not exercised after ten years,
commencing October 24, 1994.
On December 22, 1994, the Company granted to each of Jerry L. Malis and Thomas J. Gilloway
stock options to purchase 50,000 shares of Common Stock pursuant to the Plan at $2.375 per share (the closing bid price on
the NASDAQ small-cap market on December 22, 1994). Options granted expire if not exercised after ten years, commencing
December 22, 1994.
On December 22, 1995, the Company granted to it employees stock options to purchase a total of
8,000 shares of Common Stock pursuant to the Plan at $2.13 per share (the closing bid price on the NASDAQ small-cap
market on December 22, 1995). Options granted expire if not exercised after ten years, commencing December 22, 1995.
On July 26, 1996, the Company granted to it employees stock options to purchase a total of 44,000
shares of Common Stock pursuant to the Plan at $2.31 per share (the closing bid price on the NASDAQ small-cap
market on July 26, 1996). Options granted expire if not exercised after ten years, commencing July 26, 1996.
At September 30, 1996, no stock options have been exercised.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
9. COMMITMENTS AND CONTINGENCIES (continued)
Stock Option Plan (continued)
Following is a summary of the Company's non-qualified employee stock option plan:
Option Price
Shares Per Share
Options outstanding at October 1, 1993 220,000 $1.56 -$5.13
Granted - -
Exercised - -
Surrendered, forfeited or expired - -
_______ ____________
Options outstanding at September 30, 1994 220,000 $1.56 -$5.13
Granted 120,000 $2.37 -$2.50
Exercised - -
Surrendered, forfeited or expired - -
_______ ____________
Options outstanding at September 30, 1995 340,000 $1.56 -$5.13
Granted 52,000 $2.13 -$2.31
Exercised - -
Surrendered, forfeited or expired - -
_______ ____________
Options outstanding at September 30, 1996 392,000 $1.56 - $5.13
======= ============
Operating Leases
The Company currently leases approximately 4,200 square feet of office and warehouse space at a
base monthly rent of $4,362 (with increases based on increases in the consumer price index) in an office building in Oaks,
Pennsylvania, from GMM Associates, a Pennsylvania general partnership, whose partners are Jerry L. Malis, Thomas J.
Gilloway and Leonard I. Malis, principal shareholders, directors and/or officers of the Company. The lease is for
a term of five years and commenced on July 1, 1995. The related expense for this lease for the years ended September
30, 1996, 1995 and 1994 was $51,565, $51,244 and $48,707, respectively. As of September 30, 1996 the Company was
current on all rental obligations due the related party.
The Company has also entered into leases for certain equipment under operating lease agreements
with terms ranging between two and three years.
A schedule of future minimum payments under operating leases is as follows:
Year ending September 30,
1997 $ 72,572
1998 58,737
1999 52,340
2000 39,255
2001 -
_______
$222,904
=======
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
10. MAJOR CUSTOMER
For the years ended September 30, 1996, 1995 and 1994, a significant part of the Company's
revenues were derived from one major customer pursuant to distribution agreements under which the Company granted the
exclusive right to sell its electrosurgical systems and other products developed by the Company in the field of neurosurgery
through December 31, 1998. Revenues derived from this customer are as follows:
Year ended September 30, 1996 $3,055,531 89%
Year ended September 30, 1995 $2,042,990 76%
Year ended September 30, 1994 $3,246,858 90%
At September 30, 1996 and 1995, this customer accounted for approximately 76% and 67%, respectively, of the
Company's accounts receivable.
11. STOCKHOLDERS' EQUITY
Common Stock
The holders of Common Stock have no preemptive rights and the Common Stock has no redemption,
sinking fund or conversion provisions. Each share of Common Stock is entitled to one vote on any matter submitted
to the holders and to equal rights in the assets of the Company upon liquidation. All of the outstanding shares of
Common Stock are fully paid and nonassessable.
On October 14, 1992, the Board of Directors of the Company approved a stock repurchase plan
whereby the Company may, from time to time, repurchase on the open market up to 100,000 shares of the Corporation's
Common Stock. During the fiscal year ended September 30, 1995, the Company repurchased for retirement 10,000 shares at
a price of $20,542 resulting in a total of 27,500 shares repurchased since the inception of the repurchase plan at an
aggregate price of $99,924.
On August 31, 1994, in connection with the acquisition of Diversified, the Company issued 139,334
shares of unregistered Common Stock. The shares were valued at $278,668, given the restricted nature of the shares.
Preferred Stock
The Company is authorized to issue 487 shares of preferred stock, $1,000 par value. The holders of
the preferred stock have no voting rights or preemptive rights. Upon liquidation of the Company, a $1,000 per share
liquidating dividend must be paid upon each issued and outstanding share of preferred stock before any liquidating dividend is
paid upon the Common Stock.
As of September 30, 1996, there were no issued or outstanding preferred shares, and the Company
has no intention to issue any preferred stock in the immediate future.
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
12. PROVISION FOR INCOME TAXES
Provision for (benefit of) income taxes is as follows:
For the Years Ended September 30,
1996 1995 1994
____ ____ ____
Current:
Federal $ 1,736 $ (67,196) $ 73,200
State - - 156,313
______ ________ _______
1,736 (67,196) 229,513
______ ________ _______
Deferred:
Federal (49,413) (39,198) (17,589)
State 11,304 (41,997) (48,009)
_______ ________ ________
(38,109) (81,195) (65,598)
_______ ________ ________
Adjustment of deferred tax asset for state
income tax rate changes and expired net
operating loss carryforwards net of
Federal tax effect 23,394 - -
______ ________ ________
23,394 - -
______ ________ ________
$ (12,979) $(148,391) $163,915
======== ======= =======
In accordance with FASB 109, tax credits arising from net operating losses, which previously were
reported as extraordinary items, have now been restated as offsets against the provision (benefit) for income
taxes.
The Company's effective tax rate was (17.3)%, (40.8)% and 42.5% in 1996, 1995 and 1994,
respectively. Reconciliation of income tax at the statutory rate to the Company's effective rate is as follows:
For the Years Ended September 30,
1996 1995 1994
____ ____ ____
Computed at the expected statutory rate (15.0)% (34.0)% 34.0%
State taxes net of federal tax benefit 8.4 (7.6) 9.8
Reduction in state tax rate resulting from
utilization of tax loss carryforwards (8.4) - -
Research and development tax credit - - (5.0)
Other (2.3) .8 3.7
______ ______ _____
(17.3)% (40.8)% 42.5%
====== ====== =====
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
12. PROVISION FOR INCOME TAXES (Continued)
Certain items of income and expense are recognized in different years for financial reporting and
income tax purposes. Deferred income taxes are provided in recognition of these temporary differences. The items that
give rise to the deferred income tax benefit are as follows:
September 30,
1996 1995 1994
____ ____ ____
Deferred Tax Asset:
Difference in capitalization of inventory cost $ 54,106 $ 31,024 $ -
Difference in reporting bad debts 94,829 76,365 50,962
Difference in reporting depreciation - 414 -
State of Pennsylvania net operating loss
carryforward 21,159 45,780 22,207
_______ _______ ______
Total deferred tax asset 170,094 153,583 73,169
Valuation allowance (4,945) - -
_______ _______ ______
Net deferred tax asset $165,149 $153,583 $73,169
======= ======= ======
Deferred Tax Liability:
Difference in reporting depreciation $ 4,736 $ - $ 7,571
_______ _______ ______
Total Deferred Tax Liability $ 4,736 $ - $ 7,571
======= ======= ======
The Company has net operating loss carryforwards of approximately $320,000 available to reduce
future state taxable income which expire in the year ending September 30, 1998.
13. CONCENTRATION OF CREDIT RISK
The Company maintains substantially all of its banking activities with one bank. The cash balances
throughout the year generally exceed the federally insured limit of $100,000. Although management regularly monitors
its cash balances, the level of these cash balances creates an inherent concentration of credit risk.